Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717-Reference-Cited by-同舟云学术

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717

Published:2018-08-03 Issue:11 Volume:73 Page:2927-2935
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Perez-Molina J A¹^ORCID,Pulido F²,Di Giambenedetto S³,Ribera E⁴,Moreno S¹,Zamora J⁵⁶,Coscia C⁵,Alejos B⁷,Pitch J⁸,Gatell J M⁸,De Luca A⁹,Arribas J R¹⁰

Affiliation:

1. Infectious Diseases Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

2. HIV Unit, Hospital Universitario Doce de Octubre, imas12, UCM, Madrid, Spain

3. Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy

4. Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain

5. Clinical Biostatistics Unit and CIBERESP, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain

6. Queen Mary University, London, UK

7. Centro Nacional de Epidemiología, Instituto Carlos III, Madrid, Spain

8. Hospital Clínic/Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

9. UOC Malattie Infettive, Azienda Ospedaliera Universitaria Senese, and Department of Medical Biotechnologies, University of Siena, Siena, Italy

10. Hospital Universitario La Paz, IDIPAZ, Madrid, Spain

Funder

SEIMC-GeSIDA

Spanish AIDS Study Group

Spanish Society of Infectious Diseases and Clinical Microbiology

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/11/2927/26144647/dky299.pdf

Reference18 articles.

1. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M;Di Giambenedetto;J Antimicrob Chemother,2017

2. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial;Perez-Molina;Lancet Infect Dis,2015

3. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on ART: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study);Perez-Molina;J Antimicrob Chemother,2016

4. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial;Arribas;Lancet Infect Dis,2015

5. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial;Pulido;Clin Infect Dis,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multidisciplinary approach for people with HIV failing antiretroviral therapy in South Africa;Southern African Journal of HIV Medicine;2024-07-22

2. Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT);eClinicalMedicine;2024-03

3. Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges;Microorganisms;2022-02-14

4. Past and future of HIV infection. A document based on expert opinion;Revista Española de Quimioterapia;2022-01-12

5. Update and latest advances in antiretroviral therapy;Trends in Pharmacological Sciences;2022-01